STOCK TITAN

Medicenna to Present at the 2023 Guggenheim Oncology Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Medicenna Therapeutics Corp. (NASDAQ: MDNA, TSX: MDNA) announced that Dr. Fahar Merchant, President and CEO, will participate in a fireside chat at the 2023 Guggenheim Oncology Conference on February 9, 2023, at 3:55 PM ET. This conference will showcase their innovative immunotherapy developments, including the highly selective IL-2 Superkine, MDNA11, which targets cancer-killing cells. Medicenna is also advancing its IL-4 Empowered Superkine, MDNA55, which has received FDA Fast-Track and Orphan Drug designations. Interested parties can access the webcast via the provided link and find more details on Medicenna's website.

Positive
  • None.
Negative
  • None.

TORONTO and HOUSTON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President, CEO and Chairman of the Board of Medicenna, will participate in a fireside chat at the 2023 Guggenheim Oncology Conference, which is scheduled to take place from February 8 – 9, 2023.

Details on the fireside chat are as follows:

2023 Guggenheim Oncology Conference
Date:Thursday, February 9, 2023
Time:3:55 PM ET
Webcast:Link

Webcast and replay information for this event will be available on the Investor Relations section of Medicenna's website at https://ir.medicenna.com/.

About Medicenna
Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines. Medicenna’s long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity thereby preferentially stimulating cancer killing effector T cells and NK cells. Medicenna’s early-stage BiSKITs™ program, (Bifunctional SuperKine ImmunoTherapies) is designed to enhance the ability of Superkines to treat immunologically “cold” tumors. Medicenna’s IL-4 Empowered Superkine, MDNA55, has been studied in 5 clinical trials including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. MDNA55 has obtained Fast-Track and Orphan Drug status from the FDA and FDA/EMA, respectively.


FAQ

When is Medicenna's fireside chat at the Guggenheim Oncology Conference?

Medicenna's fireside chat is scheduled for February 9, 2023, at 3:55 PM ET.

Who will represent Medicenna at the Guggenheim Oncology Conference?

Dr. Fahar Merchant, President and CEO, will represent Medicenna at the conference.

Where can I watch the Medicenna webcast for the Guggenheim Oncology Conference?

The webcast can be accessed through the link provided in the press release and on Medicenna's Investor Relations website.

What is MDNA11 developed by Medicenna?

MDNA11 is a next-generation IL-2 Superkine designed to preferentially stimulate cancer-killing effector T cells and NK cells.

What is the significance of MDNA55 in Medicenna's pipeline?

MDNA55 is an IL-4 Empowered Superkine that has completed five clinical trials for recurrent GBM and has received Fast-Track and Orphan Drug designations from the FDA.

Medicenna Therapeutics Corp

NASDAQ:MDNA

MDNA Rankings

MDNA Latest News

MDNA Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link